drugset / Trial / NCT04926532
Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Toripalimab is a programmed cell death protein 1 antibody.This is an open-label, single arm, multi-center exploratory study.The objective of this study is to evaluate the efficacy and safety of therapy with toripalimab and sorafenib in patients with advanced stage hepatocellular carcinoma.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2021-10-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | — | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |